EUCTR2008-000422-39-ES
Active, not recruiting
Phase 1
Ensayo clínico en fase II aleatorizado, doble ciego, controlado con placebo para estudiar la eficacia y la seguridad de bicalutamida con o sin deforolimus en varones con cáncer de próstata asintomático metastásico y resistente a la castración. A Phase IIA Randomized, Double-blind, Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Bicalutamide with or without Deforolimus in Men with Asymptomatic, Metastatic Castrate-Resistant Prostate Cancer
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Cancer de prostata metastasico Metastatic prostate cancer
- Sponsor
- Merck & Co., Inc.
- Enrollment
- 156
- Status
- Active, not recruiting
- Last Updated
- 6 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Patient has histologically confirmed adenocarcinomas of the prostate.
- •2\. Archival pathological material is available for submission to central laboratory.
- •3\. Patient has evidence of metastatic disease at protocol entry or at the time of prior hormonal manipulation, determined radiographically by the presence of at least 2 bone scan lesions consistent with metastases or abdominal/pelvic lymph nodes \> 2 cm on longest axial measurement. Solitary or ambiguous bone lesions should be confirmed with plain radiographs or magnetic resonance imaging (MRI).
- •4\. Patient has evidence of disease progression despite castrate levels of testosterone (\< 50 ng/dl) following orchiectomy or during therapy with a luteinizing hormone releasing hormone (LHRH) agonist or antagonist (with or without an anti\-androgen). Evidence of disease progression must include one of the following:
- •a) Levels of PSA are defined as increasing when at least three consecutive measurements, obtained at least one week apart, show increases. (The minimum starting PSA level for trial entry is 10 ng/mL.)
- •b) Progressive lymph node disease is defined per Response Evaluation Criteria in Solid Tumors (RECIST) criteria. The longest diameter of any node must measure at least 2 cm on spiral computed tomography (CT) to qualify as a target lesion.
- •c) Worsening bone scan is defined as an increase of 2 or more lesions from a previous bone scan. Solitary or ambiguous bone lesions should be confirmed with plain radiographs or MRI.
- •5\. Patient has a PSA \> 10 ng/ml.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
Exclusion Criteria
- •1\. Patient has received bicalutamide, flutamide, or nilutamide within the past 12 months.
- •2\. Patient has received prior chemotherapy for metastatic prostate cancer.
- •3\. Patient has previously received rapamycin or rapamycin analogs, including deforolimus, temsirolimus, or everolimus.
- •4\. Patient is receiving corticosteroids administered at doses greater than those used for normal replacement therapy. .
- •5\. Patient is receiving an opioid or narcotic analgesic prescribed for pain due to prostate cancer.
- •6\. In the opinion of the investigator, the patient has pain related to metastatic prostate cancer that warrants the initiation of chemotherapy.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
Ensayo Clínico fase II aleatorizado, doble ciego, controlado con placebo, multicéntrico, para evaluar la eficacia y seguridad de ZACTIMA® en pacientes con Carcinoma papilar o folicular de Tiroides localmente avanzado o metastático que han fracasado al tratamiento con yodo radioactivo o que no son candidatos a recibirloA Randomized, Double Blind, placebo-controlled Phase II, Multi-Centre Study to Assess the Efficacy and Safety of Zactima™ in Patients with advanced or metastatic papillary or follicular Thyroid Carcinoma failing or unsuitable for Radioiodine therapyCarcinoma papilar o folicular de tiroides localmente avanzado o metastásicoAdvanced or metastatic papillary or follicular Thyroid CarcinomaMedDRA version: 9.1Level: LLTClassification code 10001205Term: Adenocarcinoma thyroidEUCTR2007-001890-27-ESAstraZeneca AB135
Active, not recruiting
Not Applicable
Ensayo clínico fase II, aleatorizado, triple ciego, controlado intraindividualmente con placebo, para evaluar la eficacia y seguridad de la rapamicina tópica sola o asociada a láser de colorante pulsado en pacientes con síndrome de Sturge-WeberEUCTR2010-024078-20-ESInstituto Científico y Tecnológico de Navarra
Active, not recruiting
Phase 1
Ensayo en fase II, aleatorizado, doble ciego, controlado con placebo para evaluar la eficacia y la seguridad de ZD6474 en combinación con Arimidexâ?frente a Arimidexâ?solo como tratamiento de segunda línea en pacientes con cáncer de mama avanzado (CMA) hormonosensible (receptores de estrógeno positivos y/o receptores de progesterona positivos).Cáncer de mama avanzado (CMA) hormono sensible (ER+ve y/o PR+ve)EUCTR2005-003591-38-ESAstraZeneca AB64
Active, not recruiting
Not Applicable
Estudio de fase II, aleatorizado, doble ciego, controlado con placebo, del inhibidor de MEK GSK1120212 y Gemcitabina frente a placebo y Gemcitabina en sujetos con cáncer de páncreas metastásico. A Randomized, Double-Blind Placebo-Controlled Phase II Study of the MEK inhibitor GSK1120212 plus Gemcitabine vs. Placebo plus Gemcitabine in Subjects with Metastatic Pancreatic CancerCáncer de páncreas metastásicoMedDRA version: 13Level: LLTClassification code 10033605Term: Cáncer pancreático metastásicoEUCTR2010-019578-34-ESGlaxoSmithKline, S.A.150
Active, not recruiting
Not Applicable
Estudio clínico en Fase 2, doble ciego, controlado con placebo y aleatorizado de BHQ880, anticuerpo monoclonal (AcM) anti-Dickkopf1 (DKK1), en pacientes con mieloma múltiple no tratado e insuficiencia renal - N.A.EUCTR2009-010875-26-ESovartis Farmacéutica, S.A.136